• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

The Ellipse trial: liraglutide improves glycemic control in children with type 2 diabetic on metformin

byDayton McMillan
August 15, 2019
in Chronic Disease, Endocrinology, Pediatrics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In children with type 2 diabetes (T2DM) on metformin, those randomized to liraglutide had better glycemic control after 26 weeks compared to placebo treated patients.

2. Patients treated with liraglutide experienced more adverse events and gastrointestinal issues than placebo patients.

Evidence Rating Level: 1 (Excellent)  

Study Rundown: Incidence of both childhood obesity and T2DM are increasing. Metformin is standard treatment for youth with T2DM, though second-line therapies are lacking for children compared to adults with T2DM. The glucagon-like peptide-1 analog liraglutide has shown promise in a phase 2 study in children, and further confirmation of efficacy would add to the possible treatment options for young T2DM patients. The Evaluation of Liraglutide in Pediatrics with Diabetes (Ellipse) trial showed after 26 weeks of treatment, T2DM children on metformin randomized to receive liraglutide experienced better glycemic control than placebo treated patients. Liraglutide treated patients also experienced more overall adverse events and gastrointestinal issues.

This phase 3 study provides rationale for the use of liraglutide in children with T2DM already on metformin for additional glycemic control. Strengths of the study included the randomized design and in-depth adverse event reporting, while it is limited by the length of follow-up only out to 52 weeks and the relatively small number of patients.

Click to read the study, published today in NEJM

Relevant Reading: Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009

RELATED REPORTS

Sodium-glucose cotransporter 2 inhibitors reduce heart failure hospitalization in type 2 diabetes patients

Faricimab may improve visual acuity in patients with diabetic macular edema

Supplementation of tirzepatide for type 2 diabetics on basal insulin improved glycemic control compared to placebo

In-Depth [randomized controlled trial]: This phase 3, international, randomized, placebo controlled trial enrolled patient from 2012 to 2018. Eligible patients were between 10 and 17 years old, had T2DM, had a body mass index (BMI) of greater than the 85th percentile, were treated with metformin (with or without insulin), and had glycated hemoglobin (HbA1c) levels between approximately 6.5 and 11.0%. Those with type 1 diabetes were excluded. Patients had a 11-12 week run-in period were metformin was increased to a maximum tolerated dose between 1000 and 2000mg per day followed by 8 weeks of maintenance. Patients were then randomized to received subcutaneous liraglutide (n=66, starting at 0.6mg/day with a 3-week dose escalation) or placebo (n=68) for 26 weeks in addition to a diet and exercise regimen. More patients in the liraglutide group complete 52-weeks of follow-up. The primary outcome of mean HbA1c at week 26 was reduced 0.64% from baseline in the liraglutide group and 0.42% in the placebo group (estimated treatment difference, −1.06 percentage points; 95% confidence interval [CI], −1.65 to −0.46; P<0.001). At week 52 the HbA1c treatment difference was increased (−1.30 percentage points; 95% CI, −1.89 to −0.70). Subgroup analysis showed no treatment differences across sex or age groups. More patients in the treatment group attained HbA1c levels below 7.0%. No difference in BMI was observed between groups at week 26, but by week 52 an observable decrease in BMI in liraglutide patients was observed. By week 26 mean body weight was decreased in both groups but was only maintained by week 52 in the liraglutide group. The rate of adverse events per 1 patient-year was higher in the liraglutide group. Gastrointestinal adverse events were more common in the treatment group, most notably during the first 8 weeks of treatment.

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: hemoglobin A1Cliraglutidemetforminpediatric diabetesType 2 Diabetes Mellitus
Previous Post

Poor blood pressure control from mid- through late-life increases dementia risk

Next Post

Teplizumab delays type 1 diabetes diagnosis in high risk patients

RelatedReports

Mediterranean diet linked to reduced diabetes risk in high risk cardiovascular patients
Cardiology

Sodium-glucose cotransporter 2 inhibitors reduce heart failure hospitalization in type 2 diabetes patients

June 18, 2022
Blindness and visual impairment decreasing worldwide
Chronic Disease

Faricimab may improve visual acuity in patients with diabetic macular edema

March 8, 2022
Insulin costs rose exponentially, regardless of formulation or patent
Cardiology

Supplementation of tirzepatide for type 2 diabetics on basal insulin improved glycemic control compared to placebo

February 9, 2022
Metformin treats Fragile X syndrome symptoms in mice [PreClinical]
Oncology

Metformin may improve survival for advanced lung adenocarcinoma patients with higher BMI and taking EGFR-TKI therapy

January 24, 2022
Next Post

Teplizumab delays type 1 diabetes diagnosis in high risk patients

Many new pediatric asthma cases attributable to obesity

Excess body fat is a major risk factor for premature death among Hispanic patients

Brain lesions on MRI linked with subsequent increased stroke risk

The PREVENT trial: eculizumab reduces relapse risk in patients with neuromyelitis optica and aquaporin-4 antibodies

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Hybrid immunity protects against infection with omicron variant of COVID-19
  • #VisualAbstract: Tirzepatide Once Weekly for the Treatment of Obesity
  • Wellness Check: Sleep
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.